Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.

被引：2
|
作者：
Staley, Stuart-Allison Moffat
Tucker, Katherine
Oldan, Jorge
Moore, Dominic T.
Newton, Meredith
Ertel, Michelle
West, Lindsay
Bae-Jump, Victoria
机构：
[1] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Gynecol Oncol, Chapel Hill, NC 27515 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Biostat & Data Management, Chapel Hill, NC 27515 USA
[5] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e17031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Adiposity, muscle mass and delays and dose reductions on adjuvant, taxane-based chemotherapy for breast cancer
    Feliciano, Elizabeth M. Cespedes
    Lee, Valerie
    Chen, Wendy Y.
    Prado, Carla M.
    Shachar, Shlomit S.
    Alexeeff, Stacey
    Caan, Bette J.
    CANCER RESEARCH, 2019, 79 (13)
  • [32] GUT MICROBIOME AND SYMPTOM BURDEN IN WOMEN RECEIVING TAXANE-BASED CHEMOTHERAPY FOR BREAST CANCER
    Cherwin, Catherine
    Hoang, Jemmie
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [33] Profiles of ovarian cancer patients that benefit from taxane-platinum and platinum-based chemotherapy
    Markowska, J.
    Bidziaski, M.
    Stelmachow, J.
    Kraszewska, E.
    Ziolkowska-Seta, I.
    Madry, R.
    Timorek, A.
    Rembiszewska, A.
    Kupryjaaczyk, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Cell-free DNA as a surrogate marker in patients with CRPCA undergoing taxane-based chemotherapy.
    Haidl, Friederike
    Kienel, Alexandra
    Pfister, David
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [35] Neoadjuvant Taxane-Based Combination Chemotherapy in Patients With Advanced Penile Cancer
    Djajadiningrat, Rosa S.
    Bergman, Andries M.
    van Werkhoven, Erik
    Vegt, Erik
    Horenblas, Simon
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 44 - 49
  • [36] OUTCOME PROGRESS IN PATIENTS WITH ADVANCED OVARIAN CANCER TREATED BY NEO-ADJUVANT PLATINUM/TAXANE-BASED CHEMOTHERAPY AND LATE INTERVAL DEBULKING SURGERY
    Stoeckle, E.
    Bourdarias, L.
    Guyon, F.
    Croce, S.
    Brouste, V.
    Thomas, L.
    Paute, A.
    Floquet, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [37] Survival of metastatic metaplastic breast cancer patients receiving chemotherapy.
    Kukunoor, Sparsha
    Lee, Anna
    Taiwo, Evelyn Oluwatoyin
    Schreiber, David
    Luhrs, Carol A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy
    Leonard, Robert C.
    Aapro, Matti
    Chen, Stephen
    Dirix, Luc Y.
    Mayordomo, Jose
    Reichert, Dietmar
    Untch, Michael
    ANNALS OF ONCOLOGY, 2004, 15 : 50 - 50
  • [39] BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer
    T. Ignatov
    H. Eggemann
    S. D. Costa
    A. Roessner
    T. Kalinski
    A. Ignatov
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1457 - 1463
  • [40] A Poor Predictor in Ovarian Cancer Patients Treated with Taxane-Platinum Regimen
    Felisiak-Golabek, A.
    Rembiszewska, A.
    Szafron, L.
    Chodzynska, J.
    Kwiatkowska, E.
    Rzepecka, I.
    Dansonka-Mieszkowska, A.
    Podgorska, A.
    Kupryjanczyk, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 135 - 135
12345